Latest & greatest articles for duloxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on duloxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on duloxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for duloxetine

1. Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews Full Text available with Trip Pro

Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews | Advances in Rheumatology | Full Text Search Search all BMC articles Search Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews , , & volume 60 , Article (...) number: 35 ( 2020 ) 2991 Accesses 3 Citations Abstract Background Duloxetine and amitriptyline are antidepressants used in the treatment of fibromyalgia. In published systematic reviews, there is no agreement about which drug is more effective and safer. This study aimed to compare evidence of the efficacy and safety of duloxetine compared with amitriptyline in the treatment of adult patients with fibromyalgia. This work contributes to guiding clinicians on the use of duloxetine or amitriptyline

2020 Advances in Rheumatology

2. Osteoarthritis pain getting you down? Duloxetine

Osteoarthritis pain getting you down? Duloxetine July 13, 2020 Osteoarthritis pain getting you down? Duloxetine Clinical Question: Do Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), specifically duloxetine, improve pain in patients with osteoarthritis? Bottom Line: Duloxetine can meaningfully reduce osteoarthritis pain scores (by at least 30%) for ~60% of patients compared to ~40% on placebo. An average pain of ~6 (scale 0-10) will be reduced by ~2.5 points, compared to 1.7 on placebo (...) . Duloxetine adverse effects lead to withdrawal in 12% of patients versus 6% on placebo. Evidence: • Six systematic reviews with 2-7 randomized controlled trials (RCTs) and 487-2102 patients. 1-6 Duloxetine 60-120mg daily versus placebo, results statistically significant unless indicated. o Proportion of patients attaining a meaningful pain reduction (generally =30% reduction in pain score): ? Systematic review (6 RCTs, 2060 patients) 1 of hip or knee osteoarthritis, over 10-18 weeks: 64% taking duloxetine

2020 Tools for Practice

3. Tolerability of duloxetine in the elderly and in adults: a protocol and preliminary results of a systematic review and individual participant data meta-analysis of randomized placebo-controlled trials Full Text available with Trip Pro

Tolerability of duloxetine in the elderly and in adults: a protocol and preliminary results of a systematic review and individual participant data meta-analysis of randomized placebo-controlled trials Tolerability of duloxetine in the elderly and in adults: a protocol and preliminary results of a systematic review and individual participant data meta-analysis of randomized placebo-controlled trials | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version (...) of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Protocol Tolerability of duloxetine in the elderly and in adults: a protocol and preliminary results of a systematic review and individual participant data meta-analysis

2020 Research Square

4. Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. Full Text available with Trip Pro

Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. To evaluate the risk of adverse maternal and infant outcomes following in utero exposure to duloxetine.Cohort study nested in the Medicaid Analytic eXtract for 2004-13.Publicly insured pregnancies in the United States.Pregnant women 18 to 55 years of age and their liveborn infants.Duloxetine exposure during the etiologically relevant time window, compared with no exposure to duloxetine, exposure (...) to selective serotonin reuptake inhibitors, exposure to venlafaxine, and exposure to duloxetine before but not during pregnancy.Congenital malformations overall, cardiac malformations, preterm birth, small for gestational age infant, pre-eclampsia, and postpartum hemorrhage.Cohort sizes ranged from 1.3 to 4.1 million, depending on the outcome. The number of women exposed to duloxetine varied by cohort and exposure contrast and was around 2500-3000 for early pregnancy exposure and 900-950 for late pregnancy

2020 BMJ

5. Duloxetine Reduces Pain and Improves Quality of Recovery Following Total Knee Arthroplasty in Centrally Sensitized Patients: A Prospective, Randomized Controlled Study (Abstract)

Duloxetine Reduces Pain and Improves Quality of Recovery Following Total Knee Arthroplasty in Centrally Sensitized Patients: A Prospective, Randomized Controlled Study Unexplained postoperative pain is one of the most feared complications of total knee arthroplasty (TKA). A persistent noxious peripheral stimulus, such as the pain of chronic knee osteoarthritis, can cause central sensitization in which the central nervous system becomes hyperexcitable, resulting in hypersensitivity to both (...) noxious and non-noxious stimuli. Patients with central sensitization may be more susceptible to unexplained pain after TKA. Duloxetine, a selective serotonin norepinephrine reuptake inhibitor (SNRI), can ameliorate the pain associated with central sensitization, and we aimed to determine whether it could reduce postoperative pain and improve quality of recovery after TKA in patients with central sensitization.Patients undergoing TKA were screened for central sensitization preoperatively with use

2019 EvidenceUpdates

6. Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial. Full Text available with Trip Pro

Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial. To evaluate the analgesic effect of duloxetine in Chinese patients with osteoarthritis (OA) of the knee/hip at individual patient level and report the relationship between pain intensity reduction, overall improvement, and physical functioning.Post hoc analysis of 13-week, phase 3, parallel-group, randomized, placebo-controlled study (...) of duloxetine in Chinese patients with OA pain. Patients were randomized (1:1, computer-generated, interactive web-response system) to duloxetine (60 mg once daily, n=202) or placebo (n=207). Patients, investigators, and study staff were blinded throughout the study. Duloxetine's efficacy was evaluated using the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) and the Osteoarthritis Research Society International and Outcome Measures in Rheumatology (OARSI-OMERACT

2019 Open access rheumatology : research and reviews Controlled trial quality: uncertain

7. Incontinence - urinary, in women: Duloxetine

Incontinence - urinary, in women: Duloxetine Duloxetine | Prescribing information | Incontinence - urinary, in women | CKS | NICE Search CKS… Menu Duloxetine Incontinence - urinary, in women: Duloxetine Last revised in October 2019 Duloxetine What are the cautions and contraindications for duloxetine? Do not prescribe duloxetine to people aged under 18 years, or people with: Hepatic impairment. Severe renal impairment (creatinine clearance less than 30 mL/min). Uncontrolled hypertension (...) . Prescribe duloxetine with caution to people with: A history of bleeding disorders. A history of seizures. A history of mania or bipolar disorder. Cardiac disease. Hypertension. Susceptibility to angle-closure glaucoma, or raised intraocular pressure. Susceptibility to hyponatraemia. Also prescribe with caution in elderly people. [ ; ] What dose of duloxetine should I prescribe? For the management of symptoms of stress urinary incontinence: The recommended dose of duloxetine is 40 mg taken twice a day

2019 NICE Clinical Knowledge Summaries

8. Comparison of Preoperative Administration of Pregabalin and Duloxetine on Cognitive Functions and Pain Management After Spinal Surgery: A Randomized, Double-blind, Placebo-controlled Study (Abstract)

Comparison of Preoperative Administration of Pregabalin and Duloxetine on Cognitive Functions and Pain Management After Spinal Surgery: A Randomized, Double-blind, Placebo-controlled Study Surgical trauma is known to induce hyperalgesia, and if pain management is insufficient, it contributes to persistent pain in the postoperative period.In this study, our primary aims were to compare the effect of pregabalin and duloxetine on postoperative pain scores and cognitive functions. Our secondary aim (...) hours. The second group received duloxetine 60 mg orally 1 hour before the surgery. At the postoperative 12th hour, they received a placebo capsule, and, at the 24th hour, they received duloxetine 60 mg again. The third group received placebo capsules orally at all timepoints.Postoperative pain evaluation was conducted using a Visual Analogue Scale at the postoperative first minute, 30th minute, first hour, and the 12th, 24th, and 48th hours. The preoperative and postoperative sixth hour cognitive

2018 EvidenceUpdates

9. Duloxetine

Duloxetine Top results for duloxetine - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for duloxetine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

10. A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis Full Text available with Trip Pro

A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis To examine the efficacy and safety of duloxetine in Japanese patients with knee pain due to osteoarthritis.Patients were randomized to receive duloxetine 60 mg/day or placebo for 14 weeks in a double-blind manner (ClinicalTrials.gov Identifier: NCT02248480). The primary efficacy endpoint was mean change in Brief Pain Inventory pain severity (BPI-Severity (...) ) average pain. Secondary endpoints included improvement in other BPI-Severity scales, Patient Global Impression of Improvement, Clinical Global Impressions of Severity, health-related quality of life (HRQoL) scales, range of motion of the knee joint, safety and tolerability, and structural changes on X-ray images.Of the 354 randomized patients, 161 in the duloxetine group and 162 in the placebo group completed the study. BPI-Severity average pain improved significantly with duloxetine vs. placebo

2018 EvidenceUpdates Controlled trial quality: predicted high

11. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202 Full Text available with Trip Pro

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202 Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and Drug Administration approved for treatment of multiple chronic pain disorders. We hypothesized that treatment of AIMSS with duloxetine would improve (...) average joint pain compared with placebo. Methods This randomized, double-blind, phase III trial included AI-treated postmenopausal women with early-stage breast cancer and who had average joint pain score of ≥ 4 out of 10 that developed or worsened since AI therapy initiation. Patients were randomly assigned 1:1 to duloxetine or placebo for 13 weeks. The primary end point was average joint pain through 12 weeks, examined using multivariable linear mixed models, adjusted for stratification factors

2018 EvidenceUpdates

12. Comparative Efficacy and Safety of Gabapentin, Pregabalin, Oxcarbazepine and Duloxetine in Diabetic Peripheral Neuropathy - A Network Meta-Analysis Full Text available with Trip Pro

Comparative Efficacy and Safety of Gabapentin, Pregabalin, Oxcarbazepine and Duloxetine in Diabetic Peripheral Neuropathy - A Network Meta-Analysis Comparative Efficacy and Safety of Gabapentin, Pregabalin, Oxcarbazepine and Duloxetine in Diabetic Peripheral Neuropathy - A Network Meta-Analysis Toggle navigation Proceedings for Annual Meeting of The Japanese Pharmacological Society Online ISSN : 2435-4953 / / / Article overview WCP2018 (The 18th World Congress of Basic and Clinical Pharmacology (...) ) Session ID : WCP2018_PO2-7-13 DOI Conference information Host: The Japanese Pharmacological Society, The Japanese Society of Clinical Pharmacology Name : WCP2018 (18th World Congress of Basic and Clinical Pharmacology) Location : Kyoto Date : July 01, 2018 - July 06, 2018 Poster session Comparative Efficacy and Safety of Gabapentin, Pregabalin, Oxcarbazepine and Duloxetine in Diabetic Peripheral Neuropathy - A Network Meta-Analysis , , Author information Karan B Shah Department Of Pharmacology, Smt

2018 Proceedings for Annual Meeting of The Japanese Pharmacological Society

13. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis Full Text available with Trip Pro

The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis Osteoarthritis (OA) is the most prevalent arthritis worldwide and is characterized by chronic pain and impaired physical function. We hypothesized that heightened pain in hand OA could be reduced with duloxetine or pregabalin. In this prospective, randomized clinical study, we recruited 65 participants, aged 40-75 years, with a Numerical Rating Scale (NRS) for pain (...) of at least 5. Participants were randomized to one of the following three groups: duloxetine, pregabalin, and placebo. The primary endpoint was the NRS pain score, and the secondary endpoints included the Australian and Canadian Hand Osteoarthritis Index (AUSCAN) pain, stiffness, and function scores and quantitative sensory testing by pain pressure algometry. After 13 weeks, compared to placebo, ANOVA found significant differences between the three groups (P=0.0078). In the intention-to-treat analysis

2017 EvidenceUpdates Controlled trial quality: uncertain

14. Duloxetine and Subacute Pain after Knee Arthroplasty when Added to a Multimodal Analgesic Regimen: A Randomized, Placebo-controlled, Triple-blinded Trial (Abstract)

Duloxetine and Subacute Pain after Knee Arthroplasty when Added to a Multimodal Analgesic Regimen: A Randomized, Placebo-controlled, Triple-blinded Trial Duloxetine is effective for chronic musculoskeletal and neuropathic pain, but there are insufficient data to recommend the use of antidepressants for postoperative pain. The authors hypothesized that administration of duloxetine for 15 days would reduce pain with ambulation at 2 weeks after total knee arthroplasty.In this triple-blinded (...) , randomized, placebo-controlled trial, patients received either duloxetine or placebo for 15 days, starting from the day of surgery. Patients also received a comprehensive multimodal analgesic regimen including neuraxial anesthesia, epidural analgesia, an adductor canal block, meloxicam, and oxycodone/acetaminophen as needed. The primary outcome was the pain score (0 to 10 numeric rating scale) with ambulation on postoperative day 14.One hundred six patients were randomized and analyzed. On day 14

2016 EvidenceUpdates Controlled trial quality: predicted high

15. Efficacy and Safety of Duloxetine Compared with Placebo for Diabetic Neuropathy Pain:Meta-Analysis Full Text available with Trip Pro

Efficacy and Safety of Duloxetine Compared with Placebo for Diabetic Neuropathy Pain:Meta-Analysis Hassan et al: Duloxetine in diabetic neuropathy DOI:10.19056/ijmdsjssmes/2016/v5i2/100627 IJMDS ? www.ijmds.org ? July 2016; 5(2) 1304 Review Article Efficacy and safety of Duloxetine compared with placebo for diabetic neuropathy pain: meta-analysis Hassan MA 1 , Cheng XY 2 , Dai Z 3 , Rahmathullah MN 4 , Shahnawaz 5 , Shamsa H 6 , Fathuma H 7 , Hussein AH 8 ABSTRACT Background: Duloxetine (...) to placebo for efficacy parameters, except on MNSI scale but not clinically relevant. Keywords: Duloxetine, serotonin (5-HT), nor-epinephrine, diabetic neuropathy, diabetes mellitus, MNSI, Meta-analysis Introduction Diabetes mellitus is a common disease worldwide which affects millions of people with micro and macro vascular complications, one of the significant micro- vascular complications of diabetic neuropathy which is characterized by painful, tingling and burning sensation in legs, feet and hands

2016 International Journal of Medical and Dental Sciences

16. Neuropathic pain - drug treatment: Duloxetine

Neuropathic pain - drug treatment: Duloxetine Duloxetine | Prescribing information | Neuropathic pain - drug treatment | CKS | NICE Search CKS… Menu Duloxetine Neuropathic pain - drug treatment: Duloxetine Last revised in February 2020 Duloxetine Is duloxetine licensed for neuropathic pain? Duloxetine is licensed for the treatment of diabetic peripheral neuropathic pain [ ]. However, the National Institute for Health and Care Excellence recommends duloxetine as a first-line treatment option (...) for adults with all neuropathic pain (except trigeminal neuralgia) [ ]. Dose and titration The initial dose is 60 mg once daily. If necessary, increase the dose up to a maximum of 120 mg a day (in two divided doses). Consider trialling duloxetine for up to 8 weeks before deciding it is not effective. Additional response after 8 weeks is unlikely. Reassess treatment at least every 3 months. If duloxetine is not effective or not tolerated, discontinue treatment gradually over a minimum of 1–2 weeks

2016 NICE Clinical Knowledge Summaries

17. Pharmacological interventions: Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60?years?

Pharmacological interventions: Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60?years? Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60 years? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60

2016 Evidence-Based Mental Health

18. Perioperative Duloxetine to Improve Postoperative Recovery After Abdominal Hysterectomy: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Study (Abstract)

Perioperative Duloxetine to Improve Postoperative Recovery After Abdominal Hysterectomy: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Study Postsurgical quality of recovery is worse in female than that in male patients. Duloxetine has been used successfully for the treatment of chronic pain conditions, but its use for preventing acute postoperative pain has been limited to a single previous study. More importantly, the effect of preoperative duloxetine on global postoperative (...) quality of recovery has yet to be evaluated. The main objective of the current investigation was to evaluate the effect of perioperative duloxetine on postoperative quality of recovery in women undergoing abdominal hysterectomy.The study was a prospective, randomized, placebo-controlled, double-blinded trial. Female patients undergoing abdominal hysterectomy were randomized to receive duloxetine (60 mg orally 2 hours before surgery and 24 hours after surgery) or an identical placebo pill. The primary

2016 EvidenceUpdates Controlled trial quality: predicted high

19. Duloxetine Sandoz - duloxetine

Duloxetine Sandoz - duloxetine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 23 April 2015 EMA/368328/2015 Committee for Medicinal Products for Human Use (CHMP) Withdrawal Assessment report Duloxetine Sandoz International non (...) -proprietary name: duloxetine Procedure No. EMEA/H/C/004009/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Duloxetine Sandoz EMA/368328/2015 Page 2/23 Table of Contents 1. Recommendations 5 2. Executive summary 6 2.1. Problem statement 6 2.2. About the product 6 2.3. The development programme/compliance with CHMP guidance/scientific advice 6 2.4. General comments on compliance with GMP, GLP, GCP 6 2.5. Type of application and other

2015 European Medicines Agency - EPARs

20. Duloxetine Mylan

Duloxetine Mylan 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 April 2015 EMA/CHMP/238550/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Duloxetine Mylan International non-proprietary name: duloxetine Procedure No. EMEA/H/C/003981 Note Assessment report as adopted by the CHMP with all (...) /2015 Page 4/24 1. Background information on the procedure 1.1. Submission of the dossier The applicant Generics (UK) Limited submitted on 18 August 2014 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Duloxetine Mylan, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004– ‘Generic of a centrally authorised product’. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 20 March 2014 The application

2015 European Medicines Agency - EPARs